| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 83.5 | 67.8 | 48.6 |
| Other income | 0.1 | 0.0 | 0.1 |
| Total income | 83.5 | 67.8 | 48.7 |
| Profit before exceptional items & tax | 9.0 | 8.4 | 4.2 |
| Profit before tax | 9.0 | 8.4 | 4.2 |
| Net profit | 7.0 | 5.8 | 3.1 |
| Operating margin | 10.8% | 12.4% | 8.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +125.80% |
|---|---|
| Net profit, quarter on quarter | +20.70% |
| Revenue, year on year | +71.80% |
| Operating profit, year on year | +117.10% |
| Operating profit, quarter on quarter | +6.00% |
NSE results filing, NSE: MARUSHIKA. Figures extracted from the filing.
Marushika Technology Ltd: key numbers
- Share price
- ₹120.00
- Market cap
- ₹102.4 Cr
- Revenue (annual)
- ₹116.4 Cr
- Net profit (annual)
- ₹8.95 Cr
- P/E (TTM)
- 11.4×Sector 23.8×
- Promoter holding
- 58.19%
- FII holding
- 5.58%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marushika Technology Ltd
All →Marushika Technology Earnings Call Transcript: Key Takeaways
H1 FY27 revenue ₹83.46 Cr (+71.6%) and PAT ₹7.04 Cr (+126.3%) on government project execution. Margin sustainability and defence answers gave no numbers. The ₹170 Cr FY27 target is the only hard guide.
Marushika Technology Investor Presentation: Key Takeaways
H1 FY27 revenue ₹8,346 lakh (+71.6% YoY), PAT ₹704 lakh (+126.3%), EBITDA margin 12.3%. Expansion into defence auto-tech, LMS and healthcare via Sanare partnership.
Marushika Technology Results Update
Marushika reported H1 FY27 revenue growth of 71.59% and net profit growth of 126.30% year-on-year. The release shows highlights only, not a full results statement.
Marushika Technology Other Announcement
Marushika Technology filed a Reg 27(2) non-applicability certificate for corporate governance for the half-year ended September 30, 2026. As an NSE Emerge-listed SME, the corporate governance provisions do not apply to it.
Marushika Technology Annual General Meeting
Marushika Technology Limited held its 16th Annual General Meeting on September 25, 2026. The meeting covered the adoption of financial statements and various board appointments.
Marushika Technology Partnership
Marushika Technology commenced a partnership with Sanare Medical as exclusive distributor of ExoAtlet II. The agreement targets government procurement via GeM across Indian public institutions.